Cargando…

P1099: THE SPECTRUM OF SECOND PRIMARY MALIGNANCIES AND CAUSE-SPECIFIC MORTALITY AMONG PATIENTS WITH FOLLICULAR LYMPHOMA IN THE UNITED STATES: A POPULATION-BASED STUDY.

Detalles Bibliográficos
Autores principales:	Chamarti, K., Rudraraju, V., Kiani, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430935/ http://dx.doi.org/10.1097/01.HS9.0000847264.90241.6f

Ejemplares similares

P1099: A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF PARSACLISIB, A PI3KΔ INHIBITOR, IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN CHINA: UPDATED RESULTS FROM THE STUDY
por: Zheng, Zhong, et al.
Publicado: (2023)

1099. Opportunistic Infections Among Long Term Survivors of Kidney Transplantation: Defining Risk Factors
por: Cheung, Harry, et al.
Publicado: (2020)

1099. Antibiotic Prescriptions for Acute Gastroenteritis during Office and Emergency Department Visits–United States, 2006–2015
por: Collins, Jennifer P, et al.
Publicado: (2018)

1099. The Correlation Between Antimicrobial Utilization and Resistance in a Medical Intensive Care Unit
por: Ahern, John W, et al.
Publicado: (2019)

Council Regulation (EC) No. 1099/2009: State of the Art and Its Application in a Local Health Unit in Piedmont, Italy
por: Paolucci, Ginevra, et al.
Publicado: (2015)

P1215: CHARACTERIZATION AND CLINICAL SIGNIFICANCE OF T FOLLICULAR HELPER SUBSETS IN FOLLICULAR LYMPHOMA
por: Yang, Zhi-Zhang, et al.
Publicado: (2023)

1099. Evaluation of the Safety and Pharmacokinetics (PK) following Administration of Single and Multiple Doses of Anti-Staphylococcal Lysin, LSVT-1701, in Healthy Adult Subjects
por: Wire, Mary Beth, et al.
Publicado: (2021)

The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study
por: Dinnessen, Manette A.W., et al.
Publicado: (2020)

Analysis and Follow up of Endoscopy Results in 1099 Patients with Terminal Ileum Lesions
por: Zhong, Qinglian, et al.
Publicado: (2020)

Fish welfare during slaughter: the European Council Regulation 1099/09 application
por: Mercogliano, Raffaelina, et al.
Publicado: (2023)

P1095: TREATMENT ATTRIBUTES FOR 3RD LINE FOLLICULAR LYMPHOMA TREATMENT DECISION-MAKING: PHYSICIAN PERSPECTIVES FROM A SURVEY ACROSS WESTERN EUROPE AND THE UNITED STATES
por: Johnson, P. C., et al.
Publicado: (2022)

PyMT-1099, a versatile murine cell model for EMT in breast cancer
por: Saxena, Meera, et al.
Publicado: (2018)

Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis
por: Huntington, Scott F., et al.
Publicado: (2022)

SG-APSIC1099: Scoping review of cleaning of high-touch surfaces (HTSs) in inpatient wards
por: Loo, Liang Hui, et al.
Publicado: (2023)

P1300: EPIGENETIC CHARACTERISTICS AND PROGNOSIS OF FOLLICULAR LYMPHOMA IN A SINGLE JAPANESE INSTITUTION
por: Watanabe, M., et al.
Publicado: (2022)

Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018
por: Dinnessen, Manette A. W., et al.
Publicado: (2021)

Response surface methodology-based optimization of production media and purification of α-galactosidase in solid-state fermentation by Fusarium moniliforme NCIM 1099
por: Gajdhane, Sanjivani B., et al.
Publicado: (2016)

P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
por: Dickinson, M., et al.
Publicado: (2022)

P1243: FUNCTIONAL PRECISION ONCOLOGY FOR FOLLICULAR LYMPHOMA WITH PATIENT-DERIVED XENOGRAFT IN AVIAN EMBRYOS.
por: Zala, Manon, et al.
Publicado: (2023)

Author Correction: PyMT-1099, a versatile murine cell model for EMT in breast cancer
por: Saxena, Meera, et al.
Publicado: (2020)

1099. CMV PCR Agreement between Blood and Dried Blood Spots in Infants with Congenital Cytomegalovirus Infection
por: Kim, Juhyeong, et al.
Publicado: (2023)

Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort study
por: Vaughn, John L., et al.
Publicado: (2023)

Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network
por: Crouch, Simon, et al.
Publicado: (2022)

Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
por: Serna, Angel, et al.
Publicado: (2022)

P1200: RELAPSE AND OCCURRENCE OF SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RITUXIMAB ERA, A NATIONWIDE OBSERVATIONAL STUDY
por: Lee, H. J., et al.
Publicado: (2022)

P1132: PET INTERIM RESULTS PREDICT PROGRESSION-FREE-SURVIVAL IN FOLLICULAR LYMPHOMA PATIENTS WITH ADVANCED STAGE
por: Poza, M., et al.
Publicado: (2022)

17. Assessment of Recombinant Zoster Vaccine Second Dose Completion in the United States
por: Patterson, Brandon J, et al.
Publicado: (2020)

Follicular Lymphoma
por: Yavaşoğlu, İrfan
Publicado: (2015)

Follicular lymphoma
por: Leich, Ellen
Publicado: (2019)

Second primary malignancies after treatment for malignant lymphoma
por: Okines, A, et al.
Publicado: (2005)

P1136: INTERIM IMAGING DOES NOT PREDICT CLINICAL EVOLUTION IN FOLLICULAR LYMPHOMA IN A REAL-LIFE CLINICAL SETTING
por: Ramos De Ascanio, V., et al.
Publicado: (2022)

Loco-regional recurrence trend and prognosis in young women with breast cancer according to molecular subtypes: analysis of 1099 cases
por: Li, Yang, et al.
Publicado: (2021)

Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study
por: Beiggi, S, et al.
Publicado: (2013)

P890: THE OUTCOME OF SECOND PRIMARY MALIGNANCIES DEVELOPING IN MM PATIENTS
por: Avivi, I., et al.
Publicado: (2022)

P1284: LIQUID BIOPSY BY ULTRA-DEEP SEQUENCING PLUS PET-TC MONITORING IN REAL-LIFE FOLLICULAR LYMPHOMA PATIENTS
por: Jiménez-Ubieto, A., et al.
Publicado: (2022)

P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE
por: Belada, D., et al.
Publicado: (2022)

P1095: COVID-19 VACCINE RESPONSES IN FOLLICULAR LYMPHOMA: DETERMINANTS OF HUMORAL AND CELLULAR IMMUNITY IN THE PETREA TRIAL OF FRONTLINE CHEMOIMMUNOTHERAPY
por: Jer Lim, Yeong, et al.
Publicado: (2023)

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
por: Trotman, Judith, et al.
Publicado: (2023)

P1573: EVALUATION OF THE EFFICACY OF SARS-COV-2 VACCINATION IN PATIENTS WITH FOLLICULAR LYMPHOMA DURING THE ERA OF THE COVID-19 PANDEMIC
por: Куневич, Евгений, et al.
Publicado: (2023)

Rituximab response in follicular lymphoma: contributions from KIR 2DS1 and HLA-C
por: Erbe, A K, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qreijpgoh3hgveiudibbsp80kq